Sanofi Aktie

104,18 EUR +0,92 EUR +0,89 %

21.02.2025

STU

103,26 EUR +0,48 EUR +0,47 %

21.02.2025

GVIE

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.129,85 Mrd. EUR

KGV21,10Div. Rendite4,18%

WKN920657

ISINFR0000120578

SymbolSNYNF

Sanofi Aktien News

Sortieren:Datum Meistgelesen

12.04.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - March 2024

08.04.24GlobeNewswireSanofi - AGM 30.04.2024 - Availability of Preparatory documents

04.04.24BenzingaIn Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster

04.04.24Business TimesSanofi to settle 4,000 Zantac cancer lawsuits in US state courts

22.03.24GlobeNewswirePress Release: Availability of the Q1 2024 Memorandum for modelling purposes

22.03.24EN, Sanofi-AventisPress Release: Availability of the Q1 2024 Memorandum for modelling purposes

15.03.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - February 2024

11.03.24GlobeNewswirePress Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

11.03.24EN, Sanofi-AventisPress Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

26.02.24Financial TimesBoehringer Ingelheim says weight-loss drug had positive impact on liver condition

24.02.24GlobeNewswirePress Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

24.02.24EN, Sanofi-AventisPress Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

24.02.24EN, Sanofi-AventisMedia Update: Dupixent® continues scientific leadership with late-breaking results showing reduced airway inflammation and mucus plugging in adults with uncontrolled moderate-to-severe asthma

23.02.24GlobeNewswirePress Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23.02.24EN, Sanofi-AventisPress Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

23.02.24GlobeNewswirePress Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

23.02.24EN, Sanofi-AventisPress Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation

22.02.24GlobeNewswirePress Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

22.02.24EN, Sanofi-AventisPress Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors

20.02.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - January 2024

16.02.24GlobeNewswirePress Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

16.02.24EN, Sanofi-AventisPress Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)

15.02.24GlobeNewswirePress Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

15.02.24EN, Sanofi-AventisPress Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

05.02.24GlobeNewswirePress Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses

01.02.24GlobeNewswirePress Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline

01.02.24GlobeNewswirePress Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

25.01.24GlobeNewswirePress Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)

23.01.24GlobeNewswirePress Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

23.01.24PR NewswireInhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

17.01.24GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - December 2023

09.01.24GlobeNewswirePress Release: Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee

21.12.23GlobeNewswirePress Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

18.12.23GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - November 2023

15.12.23GlobeNewswirePress Release: Availability of the Q4 2023 Memorandum for modelling purposes

15.12.23GlobeNewswirePress Release: EMA gives positive opinion to Fexinidazole Winthrop as first oral treatment of acute form of sleeping sickness (rhodesiense) found in East and Southern Africa

11.12.23GlobeNewswirePress Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

11.12.23GlobeNewswirePress Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

07.12.23GlobeNewswirePress Release: Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant

07.12.23GlobeNewswirePress Release: Sanofi Pipeline Transformation to Accelerate Growth Driven by Record Number of Potential Blockbuster Launches, Paving the Way to Industry Leadership in Immunology

Sanofi News

Sanofi News: auf dieser Seite finden Sie alle Sanofi News und Nachrichten zur Sanofi Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Sanofi News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Sanofi News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.